Skip to main content

Advertisement

SpringerLink
Log in

Risk factors and survival outcomes in patients with brain metastases from breast cancer

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Development of central nervous system (CNS) metastases in breast cancer (BC) is associated with poor prognosis. The incidence of CNS metastases in metastatic BC is reported to be about 10–16 %, but different subtypes of BC are associated with different risk of developing CNS metastases. We retrospectively analysed the risk of CNS metastases and the outcome in a cohort of 473 patients with metastatic BC. CNS metastases were diagnosed in 15.6 % of patients and median survival from diagnosis of CNS metastases was 7.53 (25th–75th 2.8–18.9) months. The risk of developing CNS metastases was higher in patients with grade 3, hormone receptor negative, HER2-positive, high Ki-67 BC. When compared to luminal A subtype, only HER2-positive BC was associated with increased risk of CNS metastases. Survival from diagnosis of CNS metastases was longer in patients with HER2-positive BC, while it was shorter in patients that did not receive any locoregional treatment, or with extra-CNS disease, or with more than 3 CNS lesions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. doi:10.3322/caac.20107

    Article  PubMed  Google Scholar 

  2. Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44–52. doi:10.1002/cncr.11859

    Article  PubMed  Google Scholar 

  3. Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277. doi:10.1200/JCO.2009.25.9820

    Article  PubMed  Google Scholar 

  4. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR (1979) The natural history of breast cancer patients with brain metastases. Cancer 44:1913–1918

    Article  PubMed  CAS  Google Scholar 

  5. Niwińska A, Murawska M, Pogoda K (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21:942–948. doi:10.1093/annonc/mdp407

    Article  PubMed  Google Scholar 

  6. Berghoff A, Bago-Horvath Z, De Vries C et al (2012) Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 106:440–446. doi:10.1038/bjc.2011.597

    Article  PubMed  CAS  Google Scholar 

  7. Kim H-J, Im S-A, Keam B et al (2012) Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. J Neurooncol 106:303–313. doi:10.1007/s11060-011-0664-8

    Article  PubMed  Google Scholar 

  8. Lee YT (1983) Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 23:175–180

    Article  PubMed  CAS  Google Scholar 

  9. Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75:5–14. doi:10.1007/s11060-004-8093-6

    Article  PubMed  Google Scholar 

  10. Posner JB (1992) Management of brain metastases. Rev Neurol (Paris) 148:477–487

    CAS  Google Scholar 

  11. Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608–3617. doi:10.1200/JCO.2004.01.175

    Article  PubMed  Google Scholar 

  12. Heitz F, Harter P, Lueck H-J et al (2009) Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 45:2792–2798. doi:10.1016/j.ejca.2009.06.027

    Article  PubMed  CAS  Google Scholar 

  13. Lin NU, Claus E, Sohl J et al (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113:2638–2645. doi:10.1002/cncr.23930

    Article  PubMed  Google Scholar 

  14. Pestalozzi BC, Zahrieh D, Price KN et al (2006) Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17:935–944. doi:10.1093/annonc/mdl064

    Article  PubMed  CAS  Google Scholar 

  15. Hicks DG, Short SM, Prescott NL et al (2006) Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 30:1097–1104. doi:10.1097/01.pas.0000213306.05811.b9

    Article  PubMed  Google Scholar 

  16. Graesslin O, Abdulkarim BS, Coutant C et al (2010) Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol 28:2032–2037. doi:10.1200/JCO.2009.24.6314

    Article  PubMed  Google Scholar 

  17. Minn AJ, Gupta GP, Padua D et al (2007) Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 104:6740–6745. doi:10.1073/pnas.0701138104

    Article  PubMed  CAS  Google Scholar 

  18. Bos PD, Zhang XH-F, Nadal C et al (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459:1005–1009. doi:10.1038/nature08021

    Article  PubMed  CAS  Google Scholar 

  19. Heitz F, Rochon J, Harter P et al (2011) Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival. Ann Oncol 22:1571–1581. doi:10.1093/annonc/mdq625

    Article  PubMed  CAS  Google Scholar 

  20. Weil RJ, Palmieri DC, Bronder JL et al (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167:913–920. doi:10.1016/S0002-9440(10)61180-7

    Article  PubMed  CAS  Google Scholar 

  21. Crivellari D, Pagani O, Veronesi A et al (2001) High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 12:353–356

    Article  PubMed  CAS  Google Scholar 

  22. Park YH, Park MJ, Ji SH et al (2009) Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 100:894–900. doi:10.1038/sj.bjc.6604941

    Article  PubMed  CAS  Google Scholar 

  23. Le Scodan R, Jouanneau L, Massard C et al (2011) Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer 11:395. doi:10.1186/1471-2407-11-395

    Article  PubMed  Google Scholar 

  24. Sperduto PW, Kased N, Roberge D et al (2012) Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 82:2111–2117. doi:10.1016/j.ijrobp.2011.02.027

    Article  PubMed  Google Scholar 

  25. Sperduto PW, Kased N, Roberge D et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419–425. doi:10.1200/JCO.2011.38.0527

    Article  PubMed  Google Scholar 

  26. Sperduto PW, Kased N, Roberge D et al (2013) The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neurooncol 112:467–472. doi:10.1007/s11060-013-1083-9

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have declared no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Oncology, University Hospital of Udine, Piazzale S.M. Misericordia, 33100, Udine, Italy

    A. M. Minisini, S. Moroso, L. Gerratana, D. Iacono, E. Poletto, M. Guardascione, C. Fontanella, G. Fasola & F. Puglisi

  2. Department of Medical and Biological Sciences, University of Udine, Udine, Italy

    M. Giangreco & F. Puglisi

Authors
  1. A. M. Minisini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Moroso
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Gerratana
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Giangreco
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Iacono
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Poletto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Guardascione
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C. Fontanella
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G. Fasola
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F. Puglisi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Puglisi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Minisini, A.M., Moroso, S., Gerratana, L. et al. Risk factors and survival outcomes in patients with brain metastases from breast cancer. Clin Exp Metastasis 30, 951–956 (2013). https://doi.org/10.1007/s10585-013-9594-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-013-9594-5

Keywords

Search

Navigation